How does your role fit into the wider landscape of the Medical Sciences?Īs said before, I am daily involved in translational leukaemia research, with the final goal to provide new treatments options to AML elderly patients my laboratory life also involves the day-to-day official supervision for Medical Sciences DPhil students. In July 2019, I have been awarded the KKLF Intermediate Research Fellowship, taking the first step needed for achieving my goal of leading my independent research group. This allowed me to generate a well-supported hypothesis regarding the role of ageing in AML progression, forming the basis for the KKLF application. I successfully identified key regulators of both declining erythropoiesis and lymphopoiesis and combined these data with similar data obtained from AML models. For this reason, in November 2015, I joined Professor Nerlov’s laboratory to start my second postdoc, where I mostly worked on haematopoietic ageing, trying to address why does the haematopoietic output of erythrocytes and lymphocytes decline with age. At that point of my career, I had a strong background in the molecular genetics of myeloid malignancies that I wanted to boost acquiring basic knowledge of normal and malignant haematopoiesis and ageing. My final goal is to determine how the aged microenvironment influences AML progression, identifying new therapeutic candidates that are likely to be useful for treating AML in the elderly.įollowing my PhD in 2014, I moved to the University of Oxford to start my first postdoc at the Blood Cancer UK Molecular Haematology Unit (RDM), where my research was focused on AML and myelodysplastic syndromes. My hypothesis is based on preliminary data obtained working on normal ageing and AML models, showing that key molecular changes that occur in bone marrow stromal cells during AML progression parallel those that are seen during normal ageing. A better understanding of how AML progression is affected by ageing is therefore urgently needed. I have a longstanding interest in leukaemia research started with my PhD and my principal aim is to understand how physiological ageing and leukemogenesis interact: Acute Myeloid Leukaemia (AML) incidence increases dramatically with age, and is far harder to treat in the elderly. I am currently a Kay Kendall Leukaemia Fund Intermediate Research Fellow (KKLF) (junior Group Leader/PI) at the MRC Weatherall Institute of Molecular Medicine (WIMM), University of Oxford. MRC Weatherall Institute of Molecular Medicine (MRC WIMM) Kay Kendall Leukaemia Fund Intermediate Research Fellow
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |